

Tax in a dot

RMC 100-2024: Updated list of VAT-exempt medicines



Stay ahead with essential tax updates

Prepared by Deloitte Philippines' tax professionals, this newsletter is crafted to provide you with timely and concise information, helping you stay compliant and strategically informed.



Carlo Navarro
SEA Transfer Pricing Leader
Philippines Tax & Legal Leader

TAX 2024-30

Updated list of VAT-exempt medicines

The Bureau of Internal Revenue (BIR) has included the following medicines for cancer, diabetes, hypertension, kidney diseases, mental illness, and tuberculosis in the published list of VAT-exempt medicines under the TRAIN Law and the CREATE Act.

A. Medicines for Cancer

Generic Name	Dosage Strength	Dosage Form
Denosumab	70 mg/mL	Solution for Injection (SC)

B. Medicines for Diabetes

Generic Name	Dosage Strength	Dosage Form
Linagliptin	5 mg	Film-Coated Tablet
Sitagliptin (as phosphate monohydrate) + Metformin hydrochloride	50 mg/500 mg	Film-Coated Tablet

Metformin Hydrochloride + Sitagliptin (as phosphate monohydrate)	1 g/50 mg	Film-Coated Tablet
--	-----------	--------------------

C. Medicines for Hypertension

Generic Name	Dosage Strength	Dosage Form
Losartan Potassium + Amlodipine (As Besilate)	100 mg/10 mg	Film-Coated Tablet
Candesartan cilexetil	32 mg	Tablet

D. Medicines for Kidney Diseases

Generic Name	Dosage Strength	Dosage Form
Finerenone	10 mg	Film-Coated Tablet
Finerenone	20 mg	Film-Coated Tablet

E. Medicines for Mental Illness

Generic Name	Dosage Strength	Dosage Form
Desvenlafaxine (as succinate monohydrate)	100 mg	Controlled-Release Tablet
Lurasidone Hydrochloride	20 mg	Film-Coated Tablet
Quetiapine (as fumarate)	200 mg	Sustained-Release Tablet

F. Medicines for Tuberculosis

Generic Name	Dosage Strength	Dosage Form
Bedaquiline (as fumarate)	100 mg	Tablet

The effectivity of the VAT exemption for the covered medicines and medical devices under the CREATE Act shall be on the date of publication of the updated list by the Food and Drug Administration (FDA).

Please see attached Revenue Memorandum Circular (RMC) No. 100-2024 for your reference.

Get in touch

Should you have any comments or questions arising from this newsletter, please contact our Tax Partners:



Carlo Navarro
Tax & Legal Leader
canavarro@deloitte.com



Senen Quizon
Tax Principal
smquizon@deloitte.com



Walter Abela Jr.
Tax Partner
wabela@deloitte.com



Alvin Saldaña
Tax Principal
asaldana@deloitte.com



Romel Curiba
Tax Principal
rcuriba@deloitte.com



Elaine de Guzman
Tax Partner
eedeguzman@deloitte.com

[Back to top](#)



[Deloitte Philippines](#)

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited (“DTTL”), its global network of member firms, and their related entities (collectively, the “Deloitte organization”). DTTL (also referred to as “Deloitte Global”) and each of its member firms and related entities are legally separate and independent entities, which cannot obligate or bind each other in respect of third parties. DTTL and each DTTL member firm and related entity is liable only for its own acts and omissions, and not those of each other. DTTL does not provide services to clients. Please see www.deloitte.com/about to learn more.

Deloitte Asia Pacific Limited is a company limited by guarantee and a member firm of DTTL. Members of Deloitte Asia Pacific Limited and their related entities, each of which are separate and independent legal entities, provide services from more than 100 cities across the region, including Auckland, Bangkok, Beijing, Hanoi, Hong Kong, Jakarta, Kuala Lumpur, Manila, Melbourne, Osaka, Seoul, Shanghai, Singapore, Sydney, Taipei and Tokyo.

About Deloitte Philippines

In the Philippines, services are provided by Landicho Abela & Co. and Navarro Amper & Co.

This communication contains general information only, and none of DTTL, its global network of member firms or their related entities is, by means of this communication, rendering professional advice or services. Before making any decision or taking any action that may affect your finances or your business, you should consult a qualified professional adviser.

No representations, warranties or undertakings (express or implied) are given as to the accuracy or completeness of the information in this communication, and none of DTTL, its member firms, related entities, employees or agents shall be liable or responsible for any loss or damage whatsoever arising directly or indirectly in connection with any person relying on this communication.

© 2024 Landicho Abela & Co.

To no longer receive emails about this topic please send a return email to the sender with the word “Unsubscribe” in the subject line.